

S1 Table. Evaluable patients' characteristics

Characteristic	No. of patients (%)
Age, median (range, yr)	59 (39-84)
Sex	
Male	112 (84.8)
Female	20 (15.2)
ECOG score	
0	38 (28.8)
1	59 (44.7)
2	35 (26.5)
Hepatitis	
No	9 (6.8)
HBV	99 (75.0)
HCV	16 (12.1)
Alcoholic	8 (6.1)
Initial CP score	
7	81 (61.4)
8	45 (34.1)
9	6 (4.5)
Tumor size, median (range, cm)	5.3 (1-21)
No. of tumors	
1	65 (49.2)
2	26 (19.7)
3	15 (11.4)
4	4 (3.0)
5	3 (2.3)
6	4 (3.0)
7	0 (0.0)
8	2 (1.5)
9	1 (0.8)
≥ 10	12 (9.1)
Tumor location	
Rt lobe	82 (62.1)
Lt lobe	15 (11.4)
Both lobes	35 (26.5)
Bile duct invasion	
No	104 (78.8)
Yes	28 (21.2)
PVTT	
No	51 (38.6)
Yes	81 (61.4)
Main PVTT	

No	96 (72.7)
Yes	36 (27.3)
mUICC_T	
1	10 (7.6)
2	19 (14.4)
3	46 (34.8)
4	57 (43.2)
mUICC_N	
0	115 (87.1)
1	17 (12.9)
Previous treatment	
No	56 (42.4)
Yes	76 (57.6)
Combined treatment	
No	50 (37.9)
Yes	82 (62.1)
AFP, median (range, IU/mL)	74.4 (2.2-973140.0)
RT technique	
3DCRT	114 (86.4)
IMRT	18 (13.6)
RT aim ^{a)}	
Curative	78 (59.1)
Palliative	54 (40.9)
Fx size, median (range, Gy)	2.5 (1.5-5.0)
Total dose, median (range, Gy)	45.0 (33.0-64.0)
BED, median (range, Gy ₁₀)	56.0 (40.4-89.6)
Classic RILD	
No	116 (87.9)
Yes	16 (12.1)
Non-classic RILD	
No	106 (80.3)
Yes	26 (19.7)
Additional Treatment	
No	58 (43.9)
Yes	74 (56.1)

ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; CP, Child-Pugh; PVTT, portal vein tumor thrombosis; mUICC, the modified International Union Against Cancer stage; T, tumor; N, lymph nodes; AFP, α -fetoprotein; RT, radiotherapy; 3DCRT, 3-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; Fx, fraction; BED, biologically effective dose when the α/β ratio was assumed to be 10 Gy; RILD, radiation- induced liver disease. ^{a)}Curative intent means that RT field cover all viable tumors; palliative intent means that RT field cover a part of viable tumors.